Cargando…

Natural approaches in metabolic syndrome management

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or “alternative”) treatments. Nutra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patti, Angelo Maria, Al-Rasadi, Khalid, Giglio, Rosaria Vincenza, Nikolic, Dragana, Mannina, Carlo, Castellino, Giuseppa, Chianetta, Roberta, Banach, Maciej, Cicero, Arrigo F.G., Lippi, Giuseppe, Montalto, Giuseppe, Rizzo, Manfredi, Toth, Peter P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	State of the Art Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868676/ https://www.ncbi.nlm.nih.gov/pubmed/29593818 http://dx.doi.org/10.5114/aoms.2017.68717

Ejemplares similares

Altilix(®) Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study
por: Castellino, Giuseppa, et al.
Publicado: (2019)

Management of Statin Intolerance in 2018: Still More Questions Than Answers
por: Toth, Peter P., et al.
Publicado: (2018)

Resveratrol and cognitive decline: a clinician perspective
por: Cicero, Arrigo F.G., et al.
Publicado: (2019)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
por: Rizzo, Manfredi, et al.
Publicado: (2016)

Statin treatment in the elderly: how much do we know?
por: Rizzo, Manfredi, et al.
Publicado: (2013)

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
por: Patti, Angelo M., et al.
Publicado: (2020)

Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects
por: Cicero, Arrigo F.G, et al.
Publicado: (2012)

The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper
por: Bielecka-Dabrowa, Agata, et al.
Publicado: (2023)

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021)

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)

A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study
por: Terzo, Simona, et al.
Publicado: (2023)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
por: Mitrovic, Bojan, et al.
Publicado: (2022)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
por: Banach, Maciej, et al.
Publicado: (2023)

Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions
por: Ertek, Sibel, et al.
Publicado: (2012)

Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology
por: Ertek, Sibel, et al.
Publicado: (2013)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Molecular mechanisms of statin intolerance
por: Gluba-Brzozka, Anna, et al.
Publicado: (2016)

The effects of statins on blood pressure: current knowledge and future perspectives
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients
por: Rysz-Górzyńska, Magdalena, et al.
Publicado: (2016)

Exosomes as nanocarriers for siRNA delivery: paradigms and challenges
por: Shahabipour, Fahimeh, et al.
Publicado: (2016)

On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020)

Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study
por: Raimondo, Stefania, et al.
Publicado: (2021)

Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease
por: Franczyk-Skóra, Beata, et al.
Publicado: (2013)

Lipids, blood pressure, kidney – what was new in 2011?
por: Barylski, Marcin, et al.
Publicado: (2011)

The role of statins in lung cancer
por: Amin, Fatemeh, et al.
Publicado: (2021)

Menopause and women’s cardiovascular health: is it really an obvious relationship?
por: Ryczkowska, Kamila, et al.
Publicado: (2022)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology
por: Anker, Markus S., et al.
Publicado: (2013)

(68)Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership
por: Carlucci, Giuseppe, et al.
Publicado: (2021)

The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer
por: Zahedi, Mohammad, et al.
Publicado: (2023)

The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
por: Pokrywka, Andrzej, et al.
Publicado: (2015)

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
por: Michalska-Kasiczak, Marta, et al.
Publicado: (2018)

Post-Transplant Complications
por: Halahleh, Khalid, et al.
Publicado: (2023)

Game of “crowning” season 8: RAS and reproductive hormones in COVID-19 – can we end this viral series?
por: Cismaru, Andrei Cosmin, et al.
Publicado: (2020)

The effects of statins on the function and differentiation of blood cells
por: Chamani, Sajjad, et al.
Publicado: (2022)

Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
por: Banach, Maciej, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2so594ck5824sl1eo8vukjjogu